FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1919810009> ?p ?o ?g. }

• W1919810009 endingPage "1345" @default.
• W1919810009 startingPage "1337" @default.
• W1919810009 abstract "To evaluate in patients with advanced colorectal cancer (CRC) three treatment regimens of oral capecitabine in order to select the most appropriate regimen for testing in phase III.Three capecitabine schedules were evaluated in a randomized phase II design: arm A, 1,331 mg/m(2)/d bid continuously; arm B, 2,510 mg/m(2)/d bid intermittently (2 weeks on/1 week off); and arm C, 1,657 mg/m(2)/d plus oral leucovorin 60 mg/d bid intermittently (2 weeks on/1 week off).One hundred nine patients were randomized; 39 patients were assessable for efficacy in arm A, 34 in arm B, and 35 in arm C. Patient characteristics were balanced in the arms. Confirmed tumor responses (partial response [PR] + complete response [CR]) were reported for eight patients with two CRs (21%; 95% confidence interval [CI], 9% to 36%) in arm A, eight patients with one CR (24%; 95% CI, 11% to 41%) in arm B, and eight patients with two CRs (23%; 95% CI, 10% to 40%) in arm C. Median times to progression (TTP) in arms A, B, and C were 127, 230, and 165 days, respectively. Overall, more toxicity was seen with capecitabine plus leucovorin, particularly diarrhea and hand-foot syndrome. There was no grade 3 or 4 marrow toxicity.Capecitabine offers a new, effective treatment option as an oral single agent in advanced CRC. Promising overall response rates were reported for all three regimens. The addition of leucovorin to the intermittent regimen had no marked effect on tumor response or median TTP. The intermittent single-agent capecitabine schedule is proposed for phase III evaluation, based on considerations of toxicity, dose-intensity, response rate, and TTP." @default.
• W1919810009 created "2016-06-24" @default.
• W1919810009 creator A5002652584 @default.
• W1919810009 creator A5003482181 @default.
• W1919810009 creator A5007926068 @default.
• W1919810009 creator A5011819733 @default.
• W1919810009 creator A5015426297 @default.
• W1919810009 creator A5021317857 @default.
• W1919810009 creator A5022173747 @default.
• W1919810009 creator A5038715594 @default.
• W1919810009 creator A5051520990 @default.
• W1919810009 creator A5053128035 @default.
• W1919810009 creator A5057771152 @default.
• W1919810009 creator A5082235252 @default.
• W1919810009 creator A5085788744 @default.
• W1919810009 creator A5090645179 @default.
• W1919810009 date "2000-03-13" @default.
• W1919810009 modified "2023-10-06" @default.
• W1919810009 title "Capecitabine, an Oral Fluoropyrimidine Carbamate With Substantial Activity in Advanced Colorectal Cancer: Results of a Randomized Phase II Study" @default.
• W1919810009 cites W1773171357 @default.
• W1919810009 cites W1832060645 @default.
• W1919810009 cites W1849818006 @default.
• W1919810009 cites W1939003096 @default.
• W1919810009 cites W1941365207 @default.
• W1919810009 cites W2006824814 @default.
• W1919810009 cites W2019908607 @default.
• W1919810009 cites W2030395635 @default.
• W1919810009 cites W2030955710 @default.
• W1919810009 cites W2044970916 @default.
• W1919810009 cites W2047453652 @default.
• W1919810009 cites W2056131235 @default.
• W1919810009 cites W2113550611 @default.
• W1919810009 cites W2118308414 @default.
• W1919810009 cites W2149505692 @default.
• W1919810009 cites W2227311140 @default.
• W1919810009 cites W2396646859 @default.
• W1919810009 cites W2602544133 @default.
• W1919810009 cites W4238668552 @default.
• W1919810009 cites W4244929598 @default.
• W1919810009 doi "https://doi.org/10.1200/jco.2000.18.6.1337" @default.
• W1919810009 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10715306" @default.
• W1919810009 hasPublicationYear "2000" @default.
• W1919810009 type Work @default.
• W1919810009 sameAs 1919810009 @default.
• W1919810009 citedByCount "304" @default.
• W1919810009 countsByYear W19198100092012 @default.
• W1919810009 countsByYear W19198100092013 @default.
• W1919810009 countsByYear W19198100092014 @default.
• W1919810009 countsByYear W19198100092015 @default.
• W1919810009 countsByYear W19198100092016 @default.
• W1919810009 countsByYear W19198100092017 @default.
• W1919810009 countsByYear W19198100092018 @default.
• W1919810009 countsByYear W19198100092019 @default.
• W1919810009 countsByYear W19198100092020 @default.
• W1919810009 countsByYear W19198100092021 @default.
• W1919810009 countsByYear W19198100092022 @default.
• W1919810009 crossrefType "journal-article" @default.
• W1919810009 hasAuthorship W1919810009A5002652584 @default.
• W1919810009 hasAuthorship W1919810009A5003482181 @default.
• W1919810009 hasAuthorship W1919810009A5007926068 @default.
• W1919810009 hasAuthorship W1919810009A5011819733 @default.
• W1919810009 hasAuthorship W1919810009A5015426297 @default.
• W1919810009 hasAuthorship W1919810009A5021317857 @default.
• W1919810009 hasAuthorship W1919810009A5022173747 @default.
• W1919810009 hasAuthorship W1919810009A5038715594 @default.
• W1919810009 hasAuthorship W1919810009A5051520990 @default.
• W1919810009 hasAuthorship W1919810009A5053128035 @default.
• W1919810009 hasAuthorship W1919810009A5057771152 @default.
• W1919810009 hasAuthorship W1919810009A5082235252 @default.
• W1919810009 hasAuthorship W1919810009A5085788744 @default.
• W1919810009 hasAuthorship W1919810009A5090645179 @default.
• W1919810009 hasConcept C121608353 @default.
• W1919810009 hasConcept C126322002 @default.
• W1919810009 hasConcept C141071460 @default.
• W1919810009 hasConcept C168563851 @default.
• W1919810009 hasConcept C2776694085 @default.
• W1919810009 hasConcept C2777909004 @default.
• W1919810009 hasConcept C2780456651 @default.
• W1919810009 hasConcept C2781413609 @default.
• W1919810009 hasConcept C29730261 @default.
• W1919810009 hasConcept C31760486 @default.
• W1919810009 hasConcept C526805850 @default.
• W1919810009 hasConcept C71924100 @default.
• W1919810009 hasConcept C90924648 @default.
• W1919810009 hasConceptScore W1919810009C121608353 @default.
• W1919810009 hasConceptScore W1919810009C126322002 @default.
• W1919810009 hasConceptScore W1919810009C141071460 @default.
• W1919810009 hasConceptScore W1919810009C168563851 @default.
• W1919810009 hasConceptScore W1919810009C2776694085 @default.
• W1919810009 hasConceptScore W1919810009C2777909004 @default.
• W1919810009 hasConceptScore W1919810009C2780456651 @default.
• W1919810009 hasConceptScore W1919810009C2781413609 @default.
• W1919810009 hasConceptScore W1919810009C29730261 @default.
• W1919810009 hasConceptScore W1919810009C31760486 @default.
• W1919810009 hasConceptScore W1919810009C526805850 @default.
• W1919810009 hasConceptScore W1919810009C71924100 @default.
• W1919810009 hasConceptScore W1919810009C90924648 @default.
• W1919810009 hasIssue "6" @default.

• next